then the everyone, our Thanks, will of us. you and status an will and our reviewing be Today, update Dr. Yvonne. Molly financial joining clinical Henderson various position. Gutierrez provide programs, on and I development Good for morning, thank
have reported clinical the encouraged by seeing out year, in we clinical in before over turning that and advance I as immunotherapy. detail. this are to programs will pipeline our to we by of historically call tumor to continuing to and types across multiple been are these highlight Dr. review data these immune particularly We further demonstrated are few a programs signals Gutierrez the items the refractory
pleased our We data are promising these ADXS-NEO, neoantigen-directed may what HOT very data portend program. our for the with preliminary from and personalized immunotherapy,
in As due we treatment important we the in have discussed cancer cancer. an neoantigens central neoantigen-directed past, to to immunotherapies paradigm become the believe the of can role addition
with shared which proprietary are approaches have express and express our neoantigens ADXS-NEO, that public targeting and that Lm antigens are antigens We platform, two antigens. other which to constructs tumor or personalized constructs ADXS-HOT,
single Through manageable that clinical generation, responses profile, of our a experience constructs, immune from Lm induction clinical demonstrate earlier antigen data trials with multiple clinical accumulated and activity. have we our safety
We disease while pursuing due waiting pace in patients of their cancer. as late-stage constructs drop including enrollment out manufactured for in and be these invariably with this trial, are program, Because often some affected. that to such are progression, will trial now personalized a those refractory is patients monotherapy to late-stage to MSS with our more of of the types patients path agents, colorectal refractory tumor immuno-oncology challenging NEO
our immunological properly NEO from however, cannot moving discerned easily which profile arm side, clinical this plus the gleaned A allows strategy from and monotherapy, guide help also in study, On safety are therapy development and data. of define studying Part The activities, our NEO monotherapy clinical will as as to neoantigen we NEO forward. information doing combination us clinical be
platform. our with experience clinical the believe We
us with their various clinical companies platforms. constructs, experience drug We from Lm neoantigen differentiates have with limited treated other who patients nearly XXX have
to ability our the immune advantage Lm the rapid on and Lm’s is mimic a effects redirect and associated have potent system. and we which cancer response by mechanism immune other functions infection against competitive natural Another unique constructs a with
from We drug have insights already valuable that insight and advance constructs. to ADXS-NEO gained platform we used our ADXS-HOT have
in an leading with year. finalize investigator-sponsored this academic discussions ADXS-HOT filed to anticipate later in will IND patients a evaluating with are trial and the construct be institution prostate We for this cancer
In drug addition, cancer next moving ADXS-HOT in to our and candidate we of for file IND forward construct expect year. first-half are with for bladder an the this
into as evaluate other collaborations. ways additional to to investigator-sponsored various through trials our the continuing bringing constructs are such of accelerate more We HOT and clinic,
its construct, study. Regarding last on AIMXCERV partial were our AXAL we our month, lifted the hold FDA announce to pleased
As the a with high cervical AXAL clinical cancer. risk, advanced locally women Phase you X AIMXCERV trial for with know, is treatment of
for We continue for cancer. AXAL, as with earlier this interim there the to analysis request potential additional study FDA with support to this we for exploring late-stage be protocol. revisions cervical other To new population are a program, partnerships for therapies regarding our for unmet among challenge provide actively need in large the dialogue is
across focused intensely healthcare are firm, our have retained constructs. our Partners, a on efforts partnering We drug advisory numerous with development us our efforts business Treehill focused assist to and
construct We co-stim with and therapies. research discussions cancer, combinations novel for pursuing to major and are indications are exploring other centers also initiate antibodies neck two trials with head for and our AXAL investigator-sponsored in targeted
duration commence later to clinical the in trial than of expect partial to quarter the XXXX, the originally of anticipated third hold. the due We first
to expected is trial start early second in XXXX. The
over Dr. Andres? our Now, programs. let Gutierrez further on clinical to me turn commentary for the call
